URBN
56
14
LH
43
-2
WM
79
3
NSC
60
3
BA
54
5
KEY
46
3
ACN
52
3
PYPL
54
2
PPL
54
-5
MCD
52
2
CSCO
67
4
DRI
53
5
FITB
63
3
SIG
52
3
GE
67
2
INTC
33
-2
MHK
49
4
R
71
4
PSX
47
2
CF
57
-2
URBN
56
14
LH
43
-2
WM
79
3
NSC
60
3
BA
54
5
KEY
46
3
ACN
52
3
PYPL
54
2
PPL
54
-5
MCD
52
2
CSCO
67
4
DRI
53
5
FITB
63
3
SIG
52
3
GE
67
2
INTC
33
-2
MHK
49
4
R
71
4
PSX
47
2
CF
57
-2
Financhill
Back

Verve Therapeutics 10K Form

Sell
25

VERV
Verve Therapeutics

Last Price:
4.85
Seasonality Move:
-11.16%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive VERV News And Ratings

See the #1 stock for the next 7 days that we like better than VERV

VERV Financial Statistics

Sales & Book Value

Annual Sales: $11.76M
Cash Flow: $-40.54M
Price / Cash Flow: 0
Annual Sales: $6.01
Price / Book: 0.81

Profitability

EPS (TTM): -2.46000
Net Income (TTM): $-197.03M
Gross Margin: --
Return on Equity: -36.52%
Return on Assets: -28.45%

Verve Therapeutics Earnings Forecast

Key Verve Therapeutics Financial Ratios

  • The Research & Development expenses have been 1,572.94% of Revenue.
  • The Net Earning history of VERV is -1,701.55% of Total Revenues.
  • Per Share Earnings over the last 5 years have been positive in 1 years.

Verve Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: VERV
Website: vervetx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 13.05
Quick Ratio: 12.72

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

VERV Technical Analysis vs Fundamental Analysis

Sell
25
Verve Therapeutics (VERV) is a Sell

Is Verve Therapeutics a Buy or a Sell?